Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions: Aptitude Medical Systems Metrix COVID/Flu Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: 2 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts

Conditions: Influenza, COVID-19, Vaccination Hesitancy
Interventions: Text message influenza vaccine reminders, Text message COVID-19 vaccine reminders, Text message influenza and COVID-19 vaccine reminders; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 17 Years
Enrollment: 66,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Itasca, Illinois • New York, New York • Philadelphia, Pennsylvania

Conditions: Influenza, Influenza, Human, Vaccine Reaction, Influenza A, Influenza Type B, Influenza A H1N1, Influenza A H3N2
Interventions: Influenza Vaccine Recipients; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: Ad26.RSV.preF, Fluarix, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Mt. Pleasant, South Carolina

Conditions: Mucosal Immune Response to Influenza Vaccination
Interventions: FluMist (Live Attenuated Influenza Vaccine); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions: Letter, Patient portal, SMS; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 43,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Influenza, Human, Influenza, Flu
Interventions: Diassess Influenza A and B Test; Device
Lead sponsor: Diassess Inc.; Industry
Eligibility: Not listed
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Influenza
Interventions: VAX102, Placebo; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Lenexa, Kansas • Nashville, Tennessee

Conditions: Childhood Influenza Vaccination, School-located Influenza Vaccination
Interventions: Text message notification; Other
Lead sponsor: University of Rochester; Other
Eligibility: 4 Years to 19 Years
Enrollment: 18,540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Fluzone; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Weeks to 22 Weeks
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Cincinnati, Ohio • Nashville, Tennessee

Conditions: Influenza, Human
Interventions: mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 12
States / cities: Glendale, Arizona • Tucson, Arizona • San Diego, California + 9 more

Conditions: Influenza (Healthy Volunteers)
Interventions: Exposure to Donors with naturally acquired influenza virus infection; Other
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Healthy
Interventions: VGX-3400X; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Overland Park, Kansas • Rockville, Maryland

Conditions: Influenza
Interventions: Fluarix™, Fluzone; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 3,327 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 40
States / cities: Antioch, California • Fairfield, California • Fresno, California + 35 more

Conditions: Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza, Healthy
Interventions: FluMist® Quadrivalent, Fluzone® Quadrivalent vaccine; Biological
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 49 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1073, mRNA-1010, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 14
States / cities: Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more

Conditions: Influenza
Interventions: Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012); Biological
Lead sponsor: PowderMed; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Lenexa, Kansas • Springfield, Missouri

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 817 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more

Conditions: Influenza
Interventions: DAS181, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: FluMist, Fluzone; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 9 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

How Healthy Adults Respond to the Nasal Flu Vaccine

Efficacy of Communication Modalities for Promoting Flu Shots

Clinical Performance of the Diassess Influenza A and B Test

Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults

Evaluation of the School Kids Influenza Prevention Project

Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age

A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

Evaluating Modes of Influenza Transmission 2b Baseline SAR

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children

Response to Influenza Vaccination in Pediatric Oncology Patients

Association Between Gut Microbiome and Dietary Determinants and Vaccine Response

Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

Genetic and Environmental Factors in the Response to Influenza Vaccination

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza Antiviral DAS-181-F04 in Healthy Adults

Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment